IPR2017-00323 Patent No. 6,943,166

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., Petitioner

v.

ICOS CORPORATION Patent Owner.

IPR2017-00323 Patent No. 6,943,166

PATENT OWNER'S OBJECTIONS TO EVIDENCE



A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Pursuant to 37 C.F.R. § 42.64(b)(1), Patent Owner submits the following objections to evidence served with the Petition for Inter Partes Review of U.S. Patent No. 6,943,166 (Paper No. 2).

Exhibit 1008- Patent Owner objects to Exhibit 1008 as lacking authentication under FRE 901 because sufficient evidence has not been provided to establish the authenticity, date of the exhibit, or its public availability prior to the critical date. No evidence establishes that Exhibit 1008 is what Petitioner claims it is. Patent Owner objects to Exhibit 1008 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as there is no admissible evidence establishing its public availability prior to the critical date of the '166 patent. Patent Owner also objects to Exhibit 1008 as hearsay (FRE 802), e.g., offering the out of court statements of various reviewers for the truth of the matters asserted (e.g., 0037, 0052, 0070, 0095, 0126, 0128, 0132, 0139, 0146, 0155, 0173, 0188, 0211, 0217, 0223, 0238, 0245, 0251, etc.); and as hearsay within hearsay (FRE 805), e.g. offering the out of court statements of the drug sponsor (e.g., 0061, 0317, 0359, 0363, 0387), pharmacologists (e.g. 0039) and test subjects (e.g., 0061, 0070, 0122, 0125, 0138, 0145, 0150, 0184, 0196, 0203, 0208, 0215, etc.) for the truth of the matters asserted.

Exhibit 1010- Patent Owner objects to Exhibit 1010 as lacking authentication under FRE 901 because sufficient evidence has not been provided to

1

establish the authenticity or date of the exhibit. No evidence establishes that Exhibit 1010 is what Petitioner claims it is. Patent Owner objects to Exhibit 1010 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as it is dated in 2015 and accessed in 2016, years after the relevant critical date of the '166 patent. Patent Owner also objects to Exhibit 1010 as hearsay (FRE 802), e.g., offering the out of court statements of the author of the document for the truth of the matter asserted.

Exhibit 1014- Patent Owner objects to Exhibit 1014 as lacking authentication under FRE 901 because sufficient evidence has not been provided to establish the authenticity, date of the exhibit, or its public availability prior to the critical date. No evidence establishes that Exhibit 1014 is what Petitioner claims it is. Patent Owner objects to Exhibit 1014 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as there is no admissible evidence establishing its public availability prior to the critical date of the '166 patent. Patent Owner also objects to Exhibit 1014 as hearsay (FRE 802), e.g., offering the out of court statements of the author of the document for the truth of the matter asserted.

Exhibit 1019- Patent Owner objects to Exhibit 1019 as lacking authentication under FRE 901 because sufficient evidence has not been provided to establish the authenticity, the date of the exhibit, or its public availability prior to

the critical date. No evidence establishes that Exhibit 1019 is what Petitioner claims it is. Patent Owner objects to Exhibit 1019 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as there is no admissible evidence establishing its public availability prior to the critical date of the '166 patent. Patent Owner also objects to Exhibit 1019 as hearsay (FRE 802), e.g., offering the out of court statements of the authors of the document for the truth of the matter asserted.

Exhibit 1020- Patent Owner objects to Exhibit 1020 as lacking authentication under FRE 901 because sufficient evidence has not been provided to establish the authenticity, the date of the exhibit, or its public availability prior to the critical date. No evidence establishes that Exhibit 1020 is what Petitioner claims it is. Patent Owner objects to Exhibit 1020 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as there is no admissible evidence establishing its public availability prior to the critical date of the '166 patent. Patent Owner also objects to Exhibit 1020 as hearsay (FRE 802), e.g., offering the out of court statements of the authors of the document for the truth of the matter asserted; and as hearsay within hearsay (FRE 805), e.g., offering the out of Court statements of Eli Lilly and Company, ICOS Corporation, George Rathmann, and August M. Watanabe for the truth of the matters asserted.

Exhibit 1021- Patent Owner objects to Exhibit 1021 as lacking authentication under FRE 901 because sufficient evidence has not been provided to establish the authenticity, the date of the exhibit, or its public availability prior to the critical date. No evidence establishes that Exhibit 1021 is what Petitioner claims it is. Patent Owner objects to Exhibit 1021 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as there is no admissible evidence establishing its public availability prior to the critical date of the '166 patent. Patent Owner also objects to Exhibit 1021 as hearsay (FRE 802), e.g., offering the out of court statements of the author of the document for the truth of the matter asserted; and as hearsay within hearsay (FRE 805), e.g., offering the out of court statements of ICOS Corp., "former collaborators," and unknown others (e.g. "[t]wo phase II studies, in 175 and 300 patients, have now been reported as completed") for the truth of the matters asserted.

Exhibit 1026- Patent Owner objects to Exhibit 1026 as lacking authentication under FRE 901 because sufficient evidence has not been provided to establish the authenticity, the date of the exhibit, or its public availability prior to the critical date. No evidence establishes that Exhibit 1026 is what Petitioner claims it is. Patent Owner objects to Exhibit 1026 as not relevant, a waste of time, and not helpful to trier of fact under FRE 402 and 403 as there is no admissible

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.